Initial exploration of Mavatar Discovery has identified biological signals that could be highly relevant to our current Alzheimer’s research identifying new targets.

This collaboration demonstrates the value of combining clinical expertise with structured, data-driven resources. It’s encouraging to see how these tools are already informing research and opening new possibilities for more precise and effective IBD care.

Alongside our broader efforts to engage the life science community around data-driven precision medicine, we also want to lower barriers to advanced analytics in areas of high unmet need.

We are pleased to collaborate with Sobi, whose deep commitment to rare diseases aligns strongly with our mission. Through advanced analytics of public transcriptomic data, we aim to contribute to a clearer understanding of IFNγ-driven mechanisms across relevant biological contexts.

Scientists no longer need to spend months cleaning datasets or building complex pipelines. With Mavatar Discovery, they can explore disease mechanisms, identify biomarkers, and generate pilot data in minutes - all without writing a single line of code.

We are very pleased to welcome Ulrika to Mavatar. Her extensive experience and broad network within Life Science make her a key part of our efforts to build strong partnerships and to further establish Mavatar in both the Nordic and global markets

Mavatar’s technology is a game-changer for drug development and personalized healthcare.

"This investment brings us closer to revolutionizing global healthcare with personalized medicine."